for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Atossa Genetics Inc

ATOS.OQ

Latest Trade

2.06USD

Change

0.05(+2.49%)

Volume

35,132

Today's Range

2.00

 - 

2.12

52 Week Range

0.81

 - 

7.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.01
Open
2.01
Volume
35,132
3M AVG Volume
8.67
Today's High
2.12
Today's Low
2.00
52 Week High
7.39
52 Week Low
0.81
Shares Out (MIL)
9.13
Market Cap (MIL)
18.35
Forward P/E
-1.21
Dividend (Yield %)
--

Next Event

Q3 2019 Atossa Genetics Inc Earnings Release

Latest Developments

More

Atossa Genetics Qtrly Loss Per Share $0.80

Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet

Atossa Genetics' Preliminary Phase 2 Study Achieves Primary Endpoint Topical Endoxifen Rapidly Reduces Breast Density

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Atossa Genetics Inc

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.

Industry

Biotechnology & Drugs

Contact Info

107 Spring St

+1.206.5880256

http://www.atossagenetics.com

Executive Leadership

Kyle Guse

Chief Financial Officer, General Counsel, Secretary

Shu-Chih Chen

Director

Stephen J. Galli

Independent Director

H. Lawrence Remmel

Independent Director

Richard I. Steinhart

Independent Director

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-29.760

2017

-10.920

2018

-5.500

2019(E)

-1.665
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.09
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.43
LT Debt To Equity (MRQ)
0.14
Return on Investment (TTM)
-107.40
Return on Equity (TTM)
-95.06

Latest News

BRIEF-Atossa Genetics Receives Positive Interim Safety Review In Phase 1 Topical Endoxifen Dose Escalation Study

* ATOSSA GENETICS RECEIVES POSITIVE INTERIM SAFETY REVIEW FROM INDEPENDENT SAFETY COMMITTEE IN PHASE 1 TOPICAL ENDOXIFEN DOSE ESCALATION STUDY IN MEN

BRIEF-Atossa Genetics Announces Quarterly Loss Per Share $0.71

* ATOSSA GENETICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Intracoastal Capital Reports 5.9 Pct passive Stake In Atossa Genetics Inc, As Of April 23, 2018

* INTRACOASTAL CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ATOSSA GENETICS INC, AS OF APRIL 23, 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2Ki2uGi) Further company coverage:

BRIEF-Atossa Genetics Receives Positive Interim Review From Independent Safety Committee In Phase 1 Topical Endoxifen Dose Escalation Study In Men

* ATOSSA GENETICS RECEIVES POSITIVE INTERIM REVIEW FROM INDEPENDENT SAFETY COMMITTEE IN PHASE 1 TOPICAL ENDOXIFEN DOSE ESCALATION STUDY IN MEN

BRIEF-Atossa Genetics Announces 1 For 12 Reverse Stock Split

* ATOSSA GENETICS INC - ANNOUNCED A REVERSE SPLIT OF ITS COMMON STOCK AT A RATIO OF 1-FOR-12, EFFECTIVE APRIL 20, 2018 Source text for Eikon: Further company coverage:

BRIEF-Atossa Genetics Announces 2017 Financial Results

* ATOSSA GENETICS ANNOUNCES 2017 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE Source text for Eikon: Further company coverage:

BRIEF-Atossa Genetics posts Q3 loss per share ‍$0.18​

* Atossa Genetics announces third quarter 2017 financial results and provides company update

BRIEF-Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics as of Oct 26 - SEC filing

* Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics Inc, as of Oct 26 - SEC filing Source text: (http://bit.ly/2iIbgjU) Further company coverage:

BRIEF-Empery Asset Management reports 9.01 pct passive stake in Atossa Genetics

* Empery Asset Management LP reports 9.01 percent passive stake in Atossa Genetics as of Oct 26 - SEC filing Source text: (http://bit.ly/2z0yYCe) Further company coverage:

BRIEF-Atossa Genetics announces pricing of $5.1 million public offering

* Atossa Genetics announces pricing of $5.1 million public offering of common stock

BRIEF-Atossa Genetics announces proposed public offering of common stock

* Atossa Genetics announces proposed public offering of common stock

BRIEF-Atossa Genetics announces upcoming Phase 2 study of topical Endoxifen

* Atossa Genetics announces upcoming Phase 2 study of topical Endoxifen

BRIEF-Atossa Genetics files for mixed shelf of upto $50 million

* Atossa Genetics Inc files for mixed shelf of upto $50 million - SEC filing Source text: [http://bit.ly/2xmdyOY] Further company coverage:

BRIEF-Atossa Genetics reports Q2 ‍loss per share $0.64​

* Atossa Genetics announces second quarter 2017 financial results and provides company update

BRIEF-Atossa Genetics receives positive safety committee assessment

* Atossa genetics says received positive interim safety assessment of first cohort receiving proprietary oral endoxifen in phase 1 dose escalation study Source text for Eikon: Further company coverage:

BRIEF-Atossa Genetics qtrly loss per share $0.45

* Atossa Genetics announces first quarter 2017 financial results and provides company update

BRIEF-Atossa Genetics qtrly loss per basic common share $0.45

* "we are in the research and development phase and do not generate revenue"

BRIEF-Atossa Genetics says second positive interim review on Phase 1 study of endoxifen may advance to final topical dosing level

* Atossa Genetics - second positive interim review on Phase 1 study of endoxifen from independent safety committee who concluded study may advance to final topical dosing level Source text for Eikon: Further company coverage:

BRIEF-Atossa Genetics receives approval from institutional review board for continuation of its fulvestrant microcatheter phase 2 study

* Atossa Genetics receives approval from institutional review board for continuation of its fulvestrant microcatheter phase 2 study

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up